# A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ

> **NCT03057912** · PHASE1 · UNKNOWN · sponsor: **First Affiliated Hospital, Sun Yat-Sen University** · enrollment: 60 (estimated)

## Conditions studied

- Human Papillomavirus-Related Malignant Neoplasm

## Interventions

- **BIOLOGICAL:** TALEN
- **BIOLOGICAL:** CRISPR/Cas9

## Key facts

- **NCT ID:** NCT03057912
- **Lead sponsor:** First Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-15
- **Primary completion:** 2018-11-15
- **Final completion:** 2019-01-15
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03057912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03057912, "A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03057912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*